aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Rating of “Hold” from Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR) has earned an average recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company.

Several equities research analysts have recently issued reports on the stock. Freedom Capital raised shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 20th. Weiss Ratings upgraded shares of aTyr Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. Millennium Management LLC boosted its position in shares of aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock worth $4,829,000 after buying an additional 1,231,052 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of aTyr Pharma by 46.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company’s stock valued at $1,155,000 after buying an additional 120,496 shares during the period. Creative Planning acquired a new position in aTyr Pharma during the 2nd quarter worth approximately $74,000. JPMorgan Chase & Co. acquired a new position in aTyr Pharma during the 2nd quarter worth approximately $208,000. Finally, Legal & General Group Plc purchased a new position in aTyr Pharma in the 2nd quarter worth approximately $49,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Stock Down 2.6%

NASDAQ ATYR opened at $0.54 on Friday. The stock has a market cap of $52.97 million, a price-to-earnings ratio of -0.87 and a beta of 0.54. The business has a fifty day moving average of $0.53 and a 200-day moving average of $0.68. aTyr Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $6.50.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. The business had revenue of $189.56 million during the quarter. As a group, analysts anticipate that aTyr Pharma will post -0.44 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.